Search Results
Search for other papers by Kjell Öberg in
Google Scholar
PubMed
Search for other papers by Steven W J Lamberts in
Google Scholar
PubMed
Introduction Somatostatin analogues are the current mainstay treatment for acromegaly and gastroenteropancreatic neuroendocrine tumours (GEP-NET). Acromegaly: background Acromegaly is a chronic metabolic disorder with an estimated
Department of Clinical Medicine and Gastroenterology, Service de Gastroentérologie, Service d'Anatomie Pathologique, INSERM U773, Service de Radiologie, Service d'Oncologie Bichat-Beaujon, St James's Hospital and Trinity College Dublin, James's Street, Dublin 8, Ireland
Search for other papers by Dermot O'Toole in
Google Scholar
PubMed
Department of Clinical Medicine and Gastroenterology, Service de Gastroentérologie, Service d'Anatomie Pathologique, INSERM U773, Service de Radiologie, Service d'Oncologie Bichat-Beaujon, St James's Hospital and Trinity College Dublin, James's Street, Dublin 8, Ireland
Search for other papers by Anne Couvelard in
Google Scholar
PubMed
Search for other papers by Vinciane Rebours in
Google Scholar
PubMed
Search for other papers by Magali Zappa in
Google Scholar
PubMed
Search for other papers by Olivia Hentic in
Google Scholar
PubMed
Search for other papers by Pascal Hammel in
Google Scholar
PubMed
Search for other papers by Philippe Levy in
Google Scholar
PubMed
Department of Clinical Medicine and Gastroenterology, Service de Gastroentérologie, Service d'Anatomie Pathologique, INSERM U773, Service de Radiologie, Service d'Oncologie Bichat-Beaujon, St James's Hospital and Trinity College Dublin, James's Street, Dublin 8, Ireland
Search for other papers by Pierre Bedossa in
Google Scholar
PubMed
Search for other papers by Eric Raymond in
Google Scholar
PubMed
Search for other papers by Philippe Ruszniewski in
Google Scholar
PubMed
responses to cytotoxics in patients with gastro-entero-pancreatic neuroendocrine tumors (GEP-NETs) vary with best responses attributable to streptozotocin-based regimens especially in pancreatic GEP ( O'Toole et al . 2004 , O'Toole 2006 ). Nonetheless
Gastrointestinal Unit, Department of Medicine, Cancer Center, Center for Computational and Integrative Biology, Department of Surgery, Department of Pathology, Department of Adult Oncology
Search for other papers by Eva-Maria Duerr in
Google Scholar
PubMed
Gastrointestinal Unit, Department of Medicine, Cancer Center, Center for Computational and Integrative Biology, Department of Surgery, Department of Pathology, Department of Adult Oncology
Search for other papers by Yusuke Mizukami in
Google Scholar
PubMed
Search for other papers by Aylwin Ng in
Google Scholar
PubMed
Gastrointestinal Unit, Department of Medicine, Cancer Center, Center for Computational and Integrative Biology, Department of Surgery, Department of Pathology, Department of Adult Oncology
Gastrointestinal Unit, Department of Medicine, Cancer Center, Center for Computational and Integrative Biology, Department of Surgery, Department of Pathology, Department of Adult Oncology
Search for other papers by Ramnik J Xavier in
Google Scholar
PubMed
Gastrointestinal Unit, Department of Medicine, Cancer Center, Center for Computational and Integrative Biology, Department of Surgery, Department of Pathology, Department of Adult Oncology
Search for other papers by Hirotoshi Kikuchi in
Google Scholar
PubMed
Search for other papers by Vikram Deshpande in
Google Scholar
PubMed
Search for other papers by Andrew L Warshaw in
Google Scholar
PubMed
Search for other papers by Jonathan Glickman in
Google Scholar
PubMed
Search for other papers by Matthew H Kulke in
Google Scholar
PubMed
Gastrointestinal Unit, Department of Medicine, Cancer Center, Center for Computational and Integrative Biology, Department of Surgery, Department of Pathology, Department of Adult Oncology
Gastrointestinal Unit, Department of Medicine, Cancer Center, Center for Computational and Integrative Biology, Department of Surgery, Department of Pathology, Department of Adult Oncology
Search for other papers by Daniel C Chung in
Google Scholar
PubMed
11248, is a novel potent inhibitor of thyroid oncogenic RET/papillary thyroid cancer kinases . Journal of Clinical Endocrinology and Metabolism 91 4070 – 4076 . Kloppel G Perren A Heitz PU 2004 The gastroenteropancreatic neuroendocrine cell system
Search for other papers by Rushabh Gujarathi in
Google Scholar
PubMed
Search for other papers by Sara Abou Azar in
Google Scholar
PubMed
Search for other papers by Joseph Tobias in
Google Scholar
PubMed
Search for other papers by Blase N Polite in
Google Scholar
PubMed
Search for other papers by Namrata Setia in
Google Scholar
PubMed
Search for other papers by Nicholas Feinberg in
Google Scholar
PubMed
Search for other papers by Daniel E Appelbaum in
Google Scholar
PubMed
Search for other papers by Xavier M Keutgen in
Google Scholar
PubMed
Search for other papers by Chih-Yi Liao in
Google Scholar
PubMed
Introduction Well-differentiated gastroenteropancreatic neuroendocrine tumors (GEP-NETs), the most common type of neuroendocrine neoplasms, are often metastatic at the time of presentation ( Yao et al. 2008 , Dasari et al. 2017 ). Peptide
Search for other papers by Mark Kidd in
Google Scholar
PubMed
Search for other papers by Ignat Drozdov in
Google Scholar
PubMed
Search for other papers by Irvin Modlin in
Google Scholar
PubMed
Introduction Biomarker assessment of gastroenteropancreatic neuroendocrine tumor (GEP–NET) disease has been difficult since the default is provided by a monoanalyte measurement, chromogranin A, which has well-described limitations ( Lawrence et al
Search for other papers by Irvin M Modlin in
Google Scholar
PubMed
Search for other papers by Ignat Drozdov in
Google Scholar
PubMed
Search for other papers by Daniele Alaimo in
Google Scholar
PubMed
Search for other papers by Stephen Callahan in
Google Scholar
PubMed
Search for other papers by Nancy Teixiera in
Google Scholar
PubMed
Search for other papers by Lisa Bodei in
Google Scholar
PubMed
Search for other papers by Mark Kidd in
Google Scholar
PubMed
Introduction Critical requirements for the management of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) include methods that efficiently detect and monitor tumor behavior ( Modlin et al . 2008 a ). NETs are, however, a heterogeneous group
Search for other papers by Martin B Niederle in
Google Scholar
PubMed
Search for other papers by Monika Hackl in
Google Scholar
PubMed
Search for other papers by Klaus Kaserer in
Google Scholar
PubMed
Search for other papers by Bruno Niederle in
Google Scholar
PubMed
gastroenteropancreatic (GEP) NETs ( Kloppel et al . 2004 ); they were formerly referred to as gastrointestinal carcinoids, a term introduced by Oberndorfer more than 100 years ago ( Kloppel 2007 a , Modlin et al . 2007 ). NETs were recently classified according to
Search for other papers by Kjell Oberg in
Google Scholar
PubMed
Introduction The clinical presentation of gastroenteropancreatic neuroendocrine tumours (GEP-NETs) varies according to the site and size of the primary tumour, the presence or absence of metastatic spread, whether associated features compatible with
Search for other papers by Mohid S Khan in
Google Scholar
PubMed
Search for other papers by Martyn E Caplin in
Google Scholar
PubMed
hemihepatectomy. Intra-operative ultrasonography is essential in detecting all metastases. Surgery can be proposed in all patients with gastroenteropancreatic-NETs (GEP-NETs) regardless of the site of primary, although resection with metastatic hindgut NETs is
Department of Internal Medicine 2, University-Hospital, Klinikum der Universität München, Ludwig-Maximilians-University of Munich, Munich, Germany
Department of Internal Medicine 4, University-Hospital, Klinikum der Universität München, Ludwig-Maximilians-University of Munich, Munich, Germany
Search for other papers by Elke Tatjana Aristizabal Prada in
Google Scholar
PubMed
Department of Internal Medicine 2, University-Hospital, Klinikum der Universität München, Ludwig-Maximilians-University of Munich, Munich, Germany
Search for other papers by Vera Heinzle in
Google Scholar
PubMed
Institute of Pathology, Ludwig-Maximilians-University of Munich, Munich, Germany
Search for other papers by Thomas Knösel in
Google Scholar
PubMed
Department of Internal Medicine 2, University-Hospital, Klinikum der Universität München, Ludwig-Maximilians-University of Munich, Munich, Germany
Department of Internal Medicine 4, University-Hospital, Klinikum der Universität München, Ludwig-Maximilians-University of Munich, Munich, Germany
Search for other papers by Svenja Nölting in
Google Scholar
PubMed
Department of Internal Medicine 2, University-Hospital, Klinikum der Universität München, Ludwig-Maximilians-University of Munich, Munich, Germany
Department of Internal Medicine 4, University-Hospital, Klinikum der Universität München, Ludwig-Maximilians-University of Munich, Munich, Germany
Search for other papers by Gerald Spöttl in
Google Scholar
PubMed
Department of Internal Medicine 2, University-Hospital, Klinikum der Universität München, Ludwig-Maximilians-University of Munich, Munich, Germany
Department of Internal Medicine 4, University-Hospital, Klinikum der Universität München, Ludwig-Maximilians-University of Munich, Munich, Germany
Search for other papers by Julian Maurer in
Google Scholar
PubMed
Department of Internal Medicine 2, University-Hospital, Klinikum der Universität München, Ludwig-Maximilians-University of Munich, Munich, Germany
Department of Internal Medicine 4, University-Hospital, Klinikum der Universität München, Ludwig-Maximilians-University of Munich, Munich, Germany
Search for other papers by Christine Spitzweg in
Google Scholar
PubMed
Department of General, Visceral, Transplantation, Vascular and Thoracic Surgery, University-Hospital, Klinikum der Universität München, Ludwig-Maximilians-University of Munich, Munich, Germany
Search for other papers by Martin Angele in
Google Scholar
PubMed
Department of Internal Medicine 2, University-Hospital, Klinikum der Universität München, Ludwig-Maximilians-University of Munich, Munich, Germany
Department of Internal Medicine 4, University-Hospital, Klinikum der Universität München, Ludwig-Maximilians-University of Munich, Munich, Germany
Search for other papers by Nina Schmidt in
Google Scholar
PubMed
Klinik für Endokrinologie, Diabetologie und Klinische Ernährung, Universitätsspital Zürich, Zurich, Switzerland
Search for other papers by Felix Beuschlein in
Google Scholar
PubMed
Search for other papers by Günter K Stalla in
Google Scholar
PubMed
Search for other papers by Rainer Blaser in
Google Scholar
PubMed
Search for other papers by Klaus A Kuhn in
Google Scholar
PubMed
Department of Internal Medicine 2, University-Hospital, Klinikum der Universität München, Ludwig-Maximilians-University of Munich, Munich, Germany
Department of Internal Medicine 4, University-Hospital, Klinikum der Universität München, Ludwig-Maximilians-University of Munich, Munich, Germany
Search for other papers by Christoph J Auernhammer in
Google Scholar
PubMed
Introduction Neuroendocrine tumors (NETs) are highly heterogeneous tumors originating from distinct cell precursors ( Schimmack et al . 2011 ). Current data show an increase in incidence of gastroenteropancreatic neuroendocrine tumors (GEP